Sol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020

Rhea-AI Summary

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) will announce its third quarter 2020 financial results on November 12, 2020, at 7:05 AM ET. The company is a clinical-stage dermatology firm that specializes in developing branded and generic topical products for skin diseases. Their innovative microencapsulation technology is being used for products such as Twyneo and Epsolay, which are under investigation for acne vulgaris and papulopustular rosacea, respectively. Other pipeline projects include SGT-210, tapinarof, and roflumilast.

Positive

• Strong pipeline with multiple products under investigation, including Twyneo and Epsolay.
• Proprietary microencapsulation technology enhances product development.

Negative

• None.

NESS ZIONA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report third quarter 2020 financial results on Thursday, November 12, 2020 at 7:05 AM ET.

About Sol-Gel Technologies

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.

For further information, please contact:

Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433

Investor Contact:
Lee M. Stern
Solebury Trout
+1-646-378-2922
lstern@soleburytrout.com

Source: Sol-Gel Technologies Ltd.

FAQ

When will Sol-Gel Technologies release its Q3 2020 financial results?

Sol-Gel Technologies will report its Q3 2020 financial results on November 12, 2020, at 7:05 AM ET.

What products is Sol-Gel Technologies developing?

Sol-Gel Technologies is developing Twyneo for acne vulgaris and Epsolay for papulopustular rosacea, among other drug products.

What is the stock symbol for Sol-Gel Technologies?

The stock symbol for Sol-Gel Technologies is SLGL.

What is the focus of Sol-Gel Technologies?

Sol-Gel Technologies focuses on identifying, developing, and commercializing topical drug products for skin diseases.